Responses
Oncology
Protocol
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.